Regeneron Says European Medicines Agency Has Accepted For Review Marketing Authorization Application For Linvoseltamab For Treatment Of Relapsed/Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Regeneron announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application for Linvoseltamab, aimed at treating relapsed/refractory multiple myeloma. This step is crucial for Regeneron as it seeks to expand its treatment portfolio in the European market.
February 02, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron's Linvoseltamab, aimed at treating relapsed/refractory multiple myeloma, has been accepted for review by the European Medicines Agency. This marks a significant step in expanding Regeneron's treatment offerings in Europe.
The acceptance of Linvoseltamab's marketing authorization application by the EMA is a positive development for Regeneron, indicating progress in its efforts to expand its product portfolio in Europe. This news is likely to be viewed favorably by investors, potentially leading to a short-term uptick in REGN's stock price due to the optimistic outlook for the drug's commercial prospects in a new market.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90